Compositions to ameliorate protein misfolding and aggregation
OwnerGuy Caldwell, Kim Caldwellinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerGuy Caldwell, Kim Caldwellinventors
Estimating the term…
The invention relates to polynucleotides comprising polynucleotide sequences corresponding to the tor-1, tor-2, ooc-5, DYT1, and DYT2 genes and parts thereof that encode polypeptide sequences and parts thereof possessing varying degrees of torsin activity, and methods of screening and amplifying polynucleotides encoding polypeptide sequences which encode polypeptides having varying degrees of TOR-1, TOR2, OOC-5 TOR-A, and TOR-B activity. Further, the invention relates to methods of reducing protein aggregation, methods of treating diseases that are caused by protein aggregation, methods of screening potential protein-aggregation-reducing products, methods of screening potential therapeutics of diseases caused by protein aggregation, and pharmaceuticals, therapeutics, and kits comprising polynucleotide sequences corresponding to the tor-1, tor-2, ooc-5, DYT1, and DYT2 genes and/or polypeptides having torsin activity.
1-61. (canceled)
An isolated polynucleotide, in association with a viral expression vector
An isolated polynucleotide, comprising a nucleic acid sequence that hybridizes to a polynucleotide comprising a sequence as set forth in SEQ ID NO:7,
A viral expression vector, comprising a nucleic acid sequence that hybridizes to a polynucleotide comprising a sequence as set forth in SEQ ID NO:
A method for producing a polynucleotide encoding a polypeptide that prevents protein misfolding and aggregation, comprising contacting a polynucleotide sample with a polynucleotide comprising at least 15 consecutive nucleotides of SEQ ID NO:7, or at least 15 consecutive nucleotides of a complement thereof.
A pharmaceutical composition for treating disorders associated with protein aggregation comprising an effective amount of a polynucleotide sequence hybridizing to a polynucleotide comprising a sequence as set forth in SEQ ID NO:7, wherein the polynucleotide is associated with a viral vector and at least one physiologically-acceptable carrier,
Dependencies are inferred from the claim text.